Modeling Pharmaceutical Powder-Flow Performance Using Particle-Size Distribution Data - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Modeling Pharmaceutical Powder-Flow Performance Using Particle-Size Distribution Data
The authors present a simple and material-sparing approach for estimating the powder-flow performance of previously uncharacterized single-component bulk powders when only particle-size distribution data are available.


Pharmaceutical Technology
Volume 33, Issue 3, pp. 126-134

Conclusion

Models have been developed for predicting relative powder-flow performance using PSD data. The PLS model, which used D10, D50, D90, and D[4,3] as input parameters, is suitable for predicting the FFC value for APIs and excipients and may also be appropriate for predicting PSD influences on other materials (e.g., active blends and active granulations). This empirical tool leverages a material and resource-sparing approach to the powder-flow performance characterization. In addition, the tool can be particularly useful during prototype drug-product design, especially with regard to risk assessments when little is known about the flow performance of a new API or excipient.

Acknowledgment

The authors would like to thank Bruno Hancock for reviewing this work and providing technical guidance.

Matthew P. Mullarney* and Norma Leyva are senior scientists at Pfizer, Inc., Eastern Point Rd., Groton, CT 06340, tel. 860.715.4139,
.

*To whom all correspondence should be addressed.

Submitted: June 16, 2008. Accepted: July 8, 2008.




What would you do differently? Submit your comments about this paper in the space below.

References

1. E.N. Hiestand, "Mechanics and Physical Principles for Powders and Compacts" (SSCI Inc., West Lafayette, IN, 2002), p 110.

2. J. Staniforth, "Powder Flow," in Pharmaceutics: The Science of Dosage Form Design, M.E. Aulton, Ed. (Churchill Livingstone, Edinburgh, UK, 2002) pp. 197–210.

3. G.E. Amidon and M.E. Houghton, "Powder Flow Testing in Preformulation and Formulation Development," Pharma. Manuf., 2 (7) 21–31 (1985).

4. A.W. Jenike, "Storage and Flow of Solids," in Utah Engineering Experiment Station Bulletin 123, 16th ed., (University of Utah, Salt Lake City, UT, 1964).

5. T. Kohler and H. Schubert, "Influence of Particle Size Distribution on the Flow Behavior of Fine Powders," Part. Syst. Charact. 8 (1–4), 101–104 (1991).

6. F. Podczeck and Y. Miah, "The Influence of Particle Size and Shape on the Angle of Internal Friction and the Flow Factor of Unlubricated and Lubricated Powders," Int. J. Pharm. 144 (2) 187–194 (1996).

7. L. Breiman et al., "Classification and Regression Trees" (Chapman & Hall/CRC, Boca Raton, FL, 1984).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here